【QUOTES DIRECTORY】 【QUOTES DIRECTORY】

More - Chris Schott Quotes

We view this as a critical event in the Pfizer story and a potential positive catalyst for the stock. - Chris Schott Quotes

We view this as a critical event in the Pfizer story and a potential positive catalyst for the stock.

A lack of mergers has allowed them to stay focused on strategy, Their alliances have been a success. - Chris Schott Quotes

A lack of mergers has allowed them to stay focused on strategy, Their alliances have been a success.

It is our top pick. I like the lack of patent expirations... They have a portfolio of new products. - Chris Schott Quotes

It is our top pick. I like the lack of patent expirations... They have a portfolio of new products.

It is our top pick. I like the lack of patent expirations...They have a portfolio of new products. - Chris Schott Quotes

It is our top pick. I like the lack of patent expirations...They have a portfolio of new products.

I think Hank's credibility has been hurt but I think he has admitted that. I think he needs to be upfront about how they are handling all the variables facing the business. - Chris Schott Quotes

I think Hank's credibility has been hurt but I think he has admitted that. I think he needs to be upfront about how they are handling all the variables facing the business.

We view this announcement, following Pfizer's 26% dividend increase in December 2005, as another sign that Pfizer is addressing shareholder concerns and as another step in the right direction for the company. - Chris Schott Quotes

We view this announcement, following Pfizer's 26% dividend increase in December 2005, as another sign that Pfizer is addressing shareholder concerns and as another step in the right direction for the company.

The company is not without controversy. - Chris Schott Quotes

The company is not without controversy.

Trading at 12 times 2005 earnings, shares are reflecting a seemingly bearish view of Pfizer's growth prospects, in our opinion. With these low expectations built into the shares, we are encouraged that Pfizer's $4 billion cost restructuring will stabilize near-term earnings. - Chris Schott Quotes

Trading at 12 times 2005 earnings, shares are reflecting a seemingly bearish view of Pfizer's growth prospects, in our opinion. With these low expectations built into the shares, we are encouraged that Pfizer's $4 billion cost restructuring will stabilize near-term earnings.

Click To See More Quotes

Quotes By Popular Topics

View All Topics (A - Z)

Like Our Facebook Page

Motivational, Inspirational, Funny Quotes